Innoviva, Inc.

Innoviva, Inc. is a diversified biopharmaceutical company with a core royalties portfolio, a critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic healthcare assets. The royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), specifically RELVAR ® /BREO ® ELLIPTA ® (fluticasone furoate/vilanterol, FF/VI) and ANORO ® ELLIPTA ® (umeclidinium bromide/vilanterol, UMEC/VI). Innoviva receives royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® at 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. Royalties from ANORO ® ELLIPTA ® sales tier upward from 6.5% to 10%. Innoviva Specialty Therapeutics is a wholly owned operating platform focused on hospitals, featuring five approved, commercial, and marketed products: GIAPREZA ® (angiotensin II) for increasing blood pressure in adults with septic or other distributive shock; XACDURO ® (sulbactam for injection; durlobactam for injection), launched in 2023, for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA ® (eravacycline) for complicated intra-abdominal infections in adults; ZEVTERA ® (ceftobiprole), licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) for U.S. commercialization and launched in the third quarter of 2025, for staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; and NUZOLVENCE ® (formerly zoliflodacin), approved by the FDA on December 12, 2025, for uncomplicated urogenital gonorrhea in adults and adolescents. The company also holds other strategic healthcare assets, including a significant stake in Armata Pharmaceuticals, Inc.